Drugs / HRS-4508
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06598735 | Sep 2024 → Dec 2027 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07140393 | Oct 2025 → Oct 2027 expected | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07232849 | Dec 2025 → Dec 2027 expected | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07003321 | Sep 2025 → Sep 2027 expected | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-4508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06598735 ↗ |
| Action | Inhibit | “an HER2 inhibitor” NCT05582499 ↗ |